A Phase 3 trial investigating the efficacy of oral acetazolamide for decongestion in patients with Heart Failure reached its primary completion date on 2025-06-30, having enrolled 130 participants.
Background
Heart failure is a chronic condition where the heart cannot pump enough blood to meet the body's needs. A common and critical aspect of managing heart failure is decongestion, which involves removing excess fluid from the body to alleviate symptoms like shortness of breath and swelling. Current standard treatment often includes diuretics such as furosemide. Exploring adjunctive therapies, like oral acetazolamide, to enhance decongestion strategies is important for improving patient outcomes and reducing the burden of symptoms associated with fluid overload in heart failure.
Trial design
This completed study, identified as Phase 3, enrolled 130 participants with Heart Failure. It was designed as a 1:1 ratio single-center, double-blind, randomized controlled trial. Participants received furosemide as standard treatment and were randomized to either 250 mg oral acetazolamide twice a day or placebo on three consecutive days. The main objective was to determine the effect of oral acetazolamide and furosemide combination therapy on decongestion. Prespecified secondary objectives included N-terminal pro B-type natriuretic peptide level on day 30, the readmission rate in a three-month period, and quality of life assessment.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for the study NCT05940220, titled "Efficacy of Oral Acetazolamide in Decongestion in Patients With Heart Failure", was recorded as primary completion on 2025-06-30 on clinicaltrials.gov.